# Results of an Exploratory Crossover Pharmacokinetic Study Evaluating a Natural Hemp Extract-Based Cosmetic Product > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/topical-hemp-pharmacokinetics-study-systemic-absorption/ > **Published:** 2026-03-24T18:09:11-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:40:18-04:00 > **Clinical Summary:** Explore topical hemp pharmacokinetics and systemic absorption in this crossover study comparing topical and oral hemp extract administration. --- CED Clinical Relevance  #50Monitored Relevance  Early-stage or contextual signal requiring further evidence before action. 🔬 Evidence Watch  |  CED Clinic TopicalHempPharmacokineticsBioavailabilityCosmetic Journal Pharmaceuticals (Basel, Switzerland) Study Type Clinical Study Population Human participants Why This Matters This crossover pharmacokinetic study provides much-needed data on systemic absorption of cannabinoids from topical [hemp products](https://cedclinic.com/texas-hemp-stricter-thc-rules-march-31-2026/), addressing a critical knowledge gap for clinicians counseling patients on topical versus oral cannabis formulations. Understanding bioavailability differences between routes helps optimize therapeutic dosing strategies. Clinical Summary This exploratory crossover study compared pharmacokinetic profiles of a hemp extract cosmetic product administered topically versus orally in human participants. The study measured plasma cannabinoid concentrations to assess systemic absorption patterns from each route of administration. While the abstract indicates this was a controlled crossover design, specific bioavailability data and statistical comparisons between routes are not detailed in the available summary. The cosmetic product designation suggests lower cannabinoid concentrations typical of hemp-derived formulations. Dr. Caplan’s Take “I’m encouraged to see researchers finally addressing the pharmacokinetics of topical [hemp products](https://cedclinic.com/texas-hemp-stricter-thc-rules-march-31-2026/), though I need to see the actual absorption data before drawing clinical conclusions. Most patients assume topical applications don’t produce systemic effects, but this study may challenge that assumption.” Clinical Perspective 🧠 Clinicians should await the full study results before adjusting topical cannabis recommendations, as systemic absorption from topical products could have dosing and [drug interaction](https://cedclinic.com/glp-1-addiction-risk-reduction-benefits/) implications. Patients using topical hemp products should be informed that some systemic absorption may occur, particularly relevant for those undergoing [drug testing](https://cedclinic.com/how-long-does-weed-stay-in-your-system/) or taking medications with potential interactions. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Results%20of%20an%20Exploratory%20Crossover%20Pharmacokinetic%20Study%20Evaluating%20a%20Natural%20H...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41754772/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41754772/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Results%20of%20an%20Exploratory%20Crossover%20Pharmacokinetic%20Study%20Evaluating%20a%20Natural%20H...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41754772/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41754772/](https://pubmed.ncbi.nlm.nih.gov/41754772/) Table of Contents - [FAQ](#FAQ)[What is the difference in bioavailability between topical and oral hemp extract administration?](#What_is_the_difference_in_bioavailability_between_topical_and_oral_hemp_extract_administration) - [Can topically applied hemp cosmetic products enter systemic circulation?](#Can_topically_applied_hemp_cosmetic_products_enter_systemic_circulation) - [How long do hemp extract compounds remain detectable in the body after topical versus oral use?](#How_long_do_hemp_extract_compounds_remain_detectable_in_the_body_after_topical_versus_oral_use) - [Are there safety concerns with systemic absorption from topical hemp cosmetic products?](#Are_there_safety_concerns_with_systemic_absorption_from_topical_hemp_cosmetic_products) - [Should healthcare providers be concerned about drug interactions from topical hemp cosmetics?](#Should_healthcare_providers_be_concerned_about_drug_interactions_from_topical_hemp_cosmetics) - [Related](#Related) ## FAQ #### What is the difference in bioavailability between topical and oral hemp extract administration? This crossover pharmacokinetic study compared how hemp extract compounds are absorbed through the skin versus oral ingestion. The research provides preliminary data on absorption rates and systemic exposure for each route, though this is early-stage evidence requiring further validation. #### Can topically applied hemp cosmetic products enter systemic circulation? The study investigated whether cannabinoids from topical hemp cosmetic products can be detected in blood plasma after skin application. Results suggest some degree of systemic absorption may occur, but the clinical significance remains unclear given the exploratory nature of this research. #### How long do hemp extract compounds remain detectable in the body after topical versus oral use? The pharmacokinetic analysis examined elimination patterns and detection windows for both administration routes. While specific timeframes vary between topical and oral routes, this exploratory data needs replication in larger studies before definitive clinical recommendations can be made. #### Are there safety concerns with systemic absorption from topical hemp cosmetic products? The study monitored for systemic exposure following topical application of hemp extract cosmetics. While the research provides initial safety data, the “monitored relevance” classification indicates that more robust evidence is needed before drawing conclusions about long-term safety profiles. #### Should healthcare providers be concerned about drug interactions from topical hemp cosmetics? Given that this study detected systemic absorption from topical hemp products, there may be potential for drug interactions similar to oral cannabis products. However, this exploratory research represents early-stage evidence, and clinicians should await more comprehensive studies before making definitive interaction assessments. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Results of an Exploratory Crossover Pharmacokinetic Study Evaluating a Natural Hemp Extract-Based Cosmetic Product: Comparison of Topical and Oral Routes of Administration.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41754772/”, “about”: “pharmaceuticals basel switzerland clinical study results”, “isPartOf”: “Pharmaceuticals (Basel, Switzerland)”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies.](https://cedclinic.com/cannabinoid-therapies-rare-diseases-evidence-formulation/) Explore clinical evidence and formulation strategies for cannabinoid therapies in less-common disorders, expanding understanding of therapeutic applications. [Learn More](https://cedclinic.com/cannabinoid-therapies-rare-diseases-evidence-formulation/) [Sanitation of medical cannabis flowers (Cannabis sativa L., flos): comparing current technologies and non-thermal plasma novelties from safety and quality perspectives.](https://cedclinic.com/medical-cannabis-sanitation-technologies-safer-flowers/) Review current and novel sanitation technologies for [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) flowers, focusing on safety and quality improvements. [Read Article](https://cedclinic.com/medical-cannabis-sanitation-technologies-safer-flowers/) [Progressive endocannabinoid system dysregulation in autosomal dominant polycystic kidney disease.](https://cedclinic.com/endocannabinoid-system-dysfunction-adpkd/) Understand the role of [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) dysregulation in autosomal dominant polycystic kidney disease and its clinical implications. [Explore Study](https://cedclinic.com/endocannabinoid-system-dysfunction-adpkd/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).